Cardiovascular disease and myocardial abnormalities in nonalcoholic fatty liver disease
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease
in many developed countries, affecting an estimated 30% of the adult population. In this …
in many developed countries, affecting an estimated 30% of the adult population. In this …
[HTML][HTML] Nonalcoholic fatty liver disease (NAFLD) and risk of cardiac arrhythmias: a new aspect of the liver-heart axis
A Mantovani - Journal of clinical and translational hepatology, 2017 - ncbi.nlm.nih.gov
Nonalcoholic fatty liver disease (NAFLD) is a pathologic condition frequently observed in
clinical practice. To date, the prevalence of NAFLD is approximately 25–30% among adults …
clinical practice. To date, the prevalence of NAFLD is approximately 25–30% among adults …
Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease
Nonalcoholic fatty liver disease (NAFLD) is a common, progressive liver disease that affects
up to one-quarter of the adult population worldwide. The clinical and economic burden of …
up to one-quarter of the adult population worldwide. The clinical and economic burden of …
[HTML][HTML] Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease
S Ballestri, A Lonardo, S Bonapace… - World journal of …, 2014 - ncbi.nlm.nih.gov
Non-alcoholic fatty liver disease (NAFLD) has emerged as a public health problem of
epidemic proportions worldwide. Accumulating clinical and epidemiological evidence …
epidemic proportions worldwide. Accumulating clinical and epidemiological evidence …
NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment
Background and aim Non-alcoholic fatty liver disease (NAFLD), affecting up to around 30%
of the world's adult population, causes considerable liver-related and extrahepatic morbidity …
of the world's adult population, causes considerable liver-related and extrahepatic morbidity …
Non‐alcoholic fatty liver disease‐related risk of cardiovascular disease and other cardiac complications
CD Byrne, G Targher - Diabetes, Obesity and Metabolism, 2022 - Wiley Online Library
Abstract Background/Aim Non‐alcoholic fatty liver disease (NAFLD) affects approximately
25% of the global adult population. The aim of this narrative review is to describe the …
25% of the global adult population. The aim of this narrative review is to describe the …
Non-alcoholic fatty liver disease and risk of cardiovascular disease
Non-alcoholic fatty liver disease (NAFLD) has become the leading cause of chronic liver
diseases worldwide, causing considerable liver-related mortality and morbidity. During the …
diseases worldwide, causing considerable liver-related mortality and morbidity. During the …
Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?
Non-alcoholic fatty liver disease (NAFLD) affects up to a third of the population worldwide
and may confer increased cardiometabolic risk with consequent adverse cardiovascular …
and may confer increased cardiometabolic risk with consequent adverse cardiovascular …
Nonalcoholic fatty liver disease as a potential risk factor of cardiovascular disease
J Luo, L Xu, J Li, S Zhao - European journal of gastroenterology & …, 2015 - journals.lww.com
Nonalcoholic fatty liver disease (NAFLD) is the hepatic component of the metabolic
syndrome. The aim of this review is to summarize the available data linking NAFLD with …
syndrome. The aim of this review is to summarize the available data linking NAFLD with …
[HTML][HTML] Nonalcoholic fatty liver disease and cardiovascular diseases: the heart of the matter
S Chiriac, C Stanciu, I Girleanu, C Cojocariu… - Canadian Journal of …, 2021 - hindawi.com
Nonalcoholic fatty liver disease (NAFLD) has emerged as the most frequent cause of liver
disease worldwide, comprising a plethora of conditions, ranging from steatosis to end-stage …
disease worldwide, comprising a plethora of conditions, ranging from steatosis to end-stage …